Role of Model-Informed Drug Development in Pediatric Drug Development, Regulatory Evaluation, and Labeling

Area of Science:

• Pharmacometrics and Drug Development
• Pediatric Pharmacology
• Regulatory Science

Background:

• Pediatric drug development faces unique challenges requiring innovative tools.
• Model-informed drug development (MIDD) provides quantitative methods to address these challenges.
• MIDD integrates existing knowledge to bridge gaps and guide decision-making.

Purpose of the Study:

• To discuss current practices and future directions for applying MIDD in pediatric drug development.
• To highlight the role of MIDD in regulatory evaluation and labeling for pediatric medicines.
• To provide examples of MIDD applications in pediatric drug research.

Main Methods:

• Leveraging existing knowledge to bridge data gaps between populations.
• Applying exposure-matching principles for pediatric dose selection and optimization.
• Utilizing physiologically based pharmacokinetic (PBPK) modeling for drug-drug interactions and ontogeny predictions.

Main Results:

• MIDD supports exposure-response similarity assumptions for knowledge transfer.
• MIDD enhances the efficiency and success rates of pediatric clinical trials.
• PBPK modeling aids in predicting drug behavior in pediatric populations, including neonates and infants.

Conclusions:

• MIDD should be integrated throughout all stages of pediatric drug development.
• Clear articulation of MIDD's strengths and limitations is crucial.
• Continued development and refinement of MIDD will improve pediatric drug development consistency and efficiency.